Abstract
Nano-engineered particles have been developed to reach specific molecular targets on diseased cells and have been used in various experimental and clinical conditions. The medical application involves diagnostic and therapeutic applications and a large deal of this research concerns malignant disease. Various approaches have been tried to effectively reach the cancer cell and PEGylated liposomes have demonstrated targeting and controlled release of antineoplastic drugs. For cancer diagnostics nanoparticles have been engineered to optimize magnetic resonance imaging, ultrasound imaging and nuclear medicine imaging. Radiolabeled nanoparticles can also be used for therapeutic purposes when tagged with appropriate radionuclides. This article aims to provide an overview how nanomedicine is presently influencing drug design and, more specifically, the development of radiopharmaceuticals for cancer management.
Keywords: Nanoparticles, nanocarriers, oncology, therapy, imaging
Current Radiopharmaceuticals
Title: Nanoparticles in Cancer
Volume: 1 Issue: 1
Author(s): Ernest K.J. Pauwels, Kalevi Kairemo, Paola Erba and Kim Bergstrom
Affiliation:
Keywords: Nanoparticles, nanocarriers, oncology, therapy, imaging
Abstract: Nano-engineered particles have been developed to reach specific molecular targets on diseased cells and have been used in various experimental and clinical conditions. The medical application involves diagnostic and therapeutic applications and a large deal of this research concerns malignant disease. Various approaches have been tried to effectively reach the cancer cell and PEGylated liposomes have demonstrated targeting and controlled release of antineoplastic drugs. For cancer diagnostics nanoparticles have been engineered to optimize magnetic resonance imaging, ultrasound imaging and nuclear medicine imaging. Radiolabeled nanoparticles can also be used for therapeutic purposes when tagged with appropriate radionuclides. This article aims to provide an overview how nanomedicine is presently influencing drug design and, more specifically, the development of radiopharmaceuticals for cancer management.
Export Options
About this article
Cite this article as:
Pauwels K.J. Ernest, Kairemo Kalevi, Erba Paola and Bergstrom Kim, Nanoparticles in Cancer, Current Radiopharmaceuticals 2008; 1 (1) . https://dx.doi.org/10.2174/1874471010801010030
DOI https://dx.doi.org/10.2174/1874471010801010030 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transition Metal-mediated Uncaging Chemistry in Prodrug Design
Current Topics in Medicinal Chemistry Therapeutic Targeting of Apoptotic Pathways: Novel Aspects in Pancreatic Cancer
Current Pharmaceutical Biotechnology Regulation of Innate Immune Responses in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Receptor Tyrosine Kinases Take a Direct Route to Mitochondria: An Overview
Current Protein & Peptide Science Radiotherapy for Brain Tumors: Current Practice and Future Directions
Current Cancer Therapy Reviews Juglone Exerts Cytotoxic, Anti-proliferative and Anti-invasive Effects on Glioblastoma Multiforme in a Cell Culture Model
Anti-Cancer Agents in Medicinal Chemistry Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94
Current Topics in Medicinal Chemistry Extra-telomeric Functions of Human Telomerase: Cancer, Mitochondria and Oxidative Stress
Current Pharmaceutical Design MicroRNA Therapeutics: the Next Magic Bullet?
Mini-Reviews in Medicinal Chemistry Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine The Role of Ghrelin Signals in Breast Cancer- A Systematic Review
Current Signal Transduction Therapy Novel Implications for Lysophospholipids, Lysophosphatidic Acid and Sphingosine 1-Phosphate, as Drug Targets in Cancer
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetics of Biotech Drugs: Peptides, Proteins and Monoclonal Antibodies
Current Drug Metabolism TGF Beta Inhibition for Cancer Therapy
Current Cancer Drug Targets Computational Analysis of miRNA and their Gene Targets Significantly Involved in Colorectal Cancer Progression
MicroRNA Magnetic Field-Assisted Gene Delivery: Achievements and Therapeutic Potential
Current Gene Therapy Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC<sup>®</sup>) in the Palliative Treatment of Pancreatic Cancer
Current Medicinal Chemistry Pancreatic Cancer: Systemic Combination Therapies for a Heterogeneous Disease
Current Pharmaceutical Design Synthesis and Evaluation of <sup>198</sup>Au/PAMAM-MPEG-FA against Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Erythropoietin: Cytoprotection in Vascular and Neuronal Cells
Current Drug Targets - Cardiovascular & Hematological Disorders